Venning Victoria, Bartlett James, Jayaram Lata
Department of Medicine, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Department of Respiratory Medicine, Western Health, Melbourne, Victoria, Australia.
Respirology. 2017 Jul;22(5):922-927. doi: 10.1111/resp.13005. Epub 2017 Feb 24.
Bronchiectasis is a growing health burden both globally and in Australasia. Associated with repeated respiratory infections, the disease often results in hospital admission, impaired quality of life, reduced lung function and shortened life expectancy. We describe the local clinical, physiological and sputum characteristics in patients hospitalized with an infective exacerbation of bronchiectasis.
This study examined the medical records of all 61 adults admitted to a metropolitan Australian hospital with an infective exacerbation of bronchiectasis in a calendar year.
Baseline characteristics include: mean (SD) age of participants was 66 (14) years; 56% were women and 42% were current or ex-smokers. The majority had other coexisting medical conditions, with asthma in 44%, COPD in 59% and both asthma and COPD in 31%. Seventy-two percent were on regular inhaled medication, 23% on cyclical antibiotics and 26% undertook regular respiratory physiotherapy. Bronchodilator reversibility was present in 17% and small airway reversibility in 41%. Sputum demonstrated normal flora in 17%, Pseudomonas aeruginosa in 32%, Haemophilus influenzae in 15% and both organisms in 17%. Mean numbers of exacerbations per year requiring hospitalization was 2.3. Sixty-two percent of subjects had an Index of Relative Socio-Economic Disadvantage in deciles 1-5. Risk factors for exacerbations included a history of asthma or COPD, documented small airway reversibility and presence of P. aeruginosa.
Patients hospitalized with an infective exacerbation of bronchiectasis are predominantly older with co-morbidities and of lower socio-economic status. Presence of P. aeruginosa was a risk factor for repeated exacerbations, as was a history of asthma, COPD or small airway reversibility.
支气管扩张在全球及澳大拉西亚地区对健康造成的负担日益加重。该疾病与反复呼吸道感染相关,常导致住院治疗、生活质量受损、肺功能下降及预期寿命缩短。我们描述了因支气管扩张感染加重而住院的患者的局部临床、生理及痰液特征。
本研究检查了澳大利亚一家大都市医院在一个日历年中因支气管扩张感染加重而入院的所有61名成年人的病历。
基线特征包括:参与者的平均(标准差)年龄为66(14)岁;56%为女性,42%为当前吸烟者或既往吸烟者。大多数人有其他并存的医疗状况,44%患有哮喘,59%患有慢性阻塞性肺疾病(COPD),31%同时患有哮喘和COPD。72%的患者定期吸入药物治疗,23%使用周期性抗生素,26%接受定期呼吸物理治疗。17%的患者支气管扩张剂可逆,41%的患者小气道可逆。痰液显示17%为正常菌群,32%为铜绿假单胞菌,15%为流感嗜血杆菌,17%为两种细菌均有。每年需要住院治疗的加重发作平均次数为2.3次。62%的受试者社会经济相对不利指数处于第1 - 5十分位数。加重发作的危险因素包括哮喘或COPD病史、记录的小气道可逆性以及铜绿假单胞菌的存在。
因支气管扩张感染加重而住院的患者主要为老年人,伴有合并症且社会经济地位较低。铜绿假单胞菌的存在是反复加重发作的危险因素,哮喘、COPD病史或小气道可逆性也是如此。